Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Revolution Medicines Inc. Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.32 (market cap $40.01B), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) and Revolution Medicines Inc. Common Stock are close in size by market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.14% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 1 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| HLN | RVMD | |
|---|---|---|
Market Cap | $40.01B | $40.32B |
Volume | 19,985,935 | 4,855,734 |
Sector | Health | Health |
52-Week High | $11.27 | $221.15 |
52-Week Low | $8.70 | $47.50 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $49.79B | $37.02B |
Dividend Yield | 2.14% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
